Literature DB >> 11417859

IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

B E Barton1.   

Abstract

An estimated 30% of cancer deaths are attributed to cachexia and its consequences. Cachexia (wasting syndrome) is the hypercatabolism of the body's carbon sources, proteins and lipids, for conversion into energy. It is induced by a variety of pathological conditions, including cancer. Among the inflammatory responses to cancer is the synthesis of cytokines, including IL-6 and related cytokines. These cytokines have been found to induce cachexia by altering metabolism of lipids and proteins. IL-6-like cytokines have been found to inhibit lipid biosynthesis by adipocytes, which increased the rate of lipid catabolism. Others have described the atrophy and increased catabolism of muscle protein due to IL-6. A cytokine closely-related to IL-6 is leptin, which plays a major role in lipid metabolism under normal conditions. The role of leptin in pathological conditions such as cancer cachexia has not yet been fully elucidated. Detailed mechanistic information about the induction of cancer cachexia by IL-6-like cytokines requires more research.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11417859     DOI: 10.1385/IR:23:1:41

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  202 in total

1.  Biomedicine. Protein loss in cancer cachexia.

Authors:  M J Tisdale
Journal:  Science       Date:  2000-09-29       Impact factor: 47.728

2.  Cytokine inhibition by a novel steroid, mometasone furoate.

Authors:  B E Barton; J P Jakway; S R Smith; M I Siegel
Journal:  Immunopharmacol Immunotoxicol       Date:  1991       Impact factor: 2.730

3.  Early onset of reproductive function in normal female mice treated with leptin.

Authors:  F F Chehab; K Mounzih; R Lu; M E Lim
Journal:  Science       Date:  1997-01-03       Impact factor: 47.728

4.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors:  X G Zhang; B Klein; R Bataille
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

5.  Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice.

Authors:  M D Barrachina; V Martínez; L Wang; J Y Wei; Y Taché
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

Review 6.  Nuclear signaling by interleukin-6.

Authors:  S Chen-Kiang; W Hsu; Y Natkunam; X Zhang
Journal:  Curr Opin Immunol       Date:  1993-02       Impact factor: 7.486

7.  Interleukin-6-induced protection in hyperoxic acute lung injury.

Authors:  N S Ward; A B Waxman; R J Homer; L L Mantell; O Einarsson; Y Du; J A Elias
Journal:  Am J Respir Cell Mol Biol       Date:  2000-05       Impact factor: 6.914

8.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

Authors:  D Aderka; J M Le; J Vilcek
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

9.  Impaired Stat3 activation following localized inflammatory stimulus in IL-6-deficient mice.

Authors:  T Alonzi; E Fattori; M Cappelletti; G Ciliberto; V Poli
Journal:  Cytokine       Date:  1998-01       Impact factor: 3.861

10.  Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo.

Authors:  R S Perlstein; E H Mougey; W E Jackson; R Neta
Journal:  Lymphokine Cytokine Res       Date:  1991-04
View more
  28 in total

Review 1.  The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Jason D Gardner; Amanda L Chancey; James A Stewart
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

2.  Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).

Authors:  Shun Sasaki; Eiji Oki; Hiroshi Saeki; Takayuki Shimose; Sanae Sakamoto; Qingjiang Hu; Kensuke Kudo; Yasuo Tsuda; Yuichiro Nakashima; Koji Ando; Yoshito Akagi; Yoshihiro Kakeji; Hideo Baba; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2019-05-06       Impact factor: 3.402

3.  Nerve growth factor links oral cancer progression, pain, and cachexia.

Authors:  Yi Ye; Dongmin Dang; Jianan Zhang; Chi T Viet; David K Lam; John C Dolan; Jennifer L Gibbs; Brian L Schmidt
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

4.  Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma.

Authors:  Biswajit Chakraborty; Ramkrishna Pal; Mohammed Ali; Leichombam Mohindro Singh; Dewan Shahidur Rahman; Sujit Kumar Ghosh; Mahuya Sengupta
Journal:  Cell Mol Immunol       Date:  2015-05-04       Impact factor: 11.530

5.  Cholesterol metabolism in active Crohn's disease.

Authors:  Vladimír Hrabovský; Zdenek Zadák; Vladimír Bláha; Radomír Hyspler; Tomás Karlík; Arnost Martínek; Alice Mendlová
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

6.  Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.

Authors:  Joshua R Huot; Leah J Novinger; Fabrizio Pin; Ashok Narasimhan; Teresa A Zimmers; Thomas M O'Connell; Andrea Bonetto
Journal:  JCI Insight       Date:  2020-05-07

7.  Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications.

Authors:  Maria Dalamaga
Journal:  World J Exp Med       Date:  2013-08-20

Review 8.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

9.  The effect of high-altitude on human skeletal muscle energetics: P-MRS results from the Caudwell Xtreme Everest expedition.

Authors:  Lindsay M Edwards; Andrew J Murray; Damian J Tyler; Graham J Kemp; Cameron J Holloway; Peter A Robbins; Stefan Neubauer; Denny Levett; Hugh E Montgomery; Mike P Grocott; Kieran Clarke
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

10.  TNFalpha shedding and epidermal inflammation are controlled by Jun proteins.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; Denes Hnisz; Martin Holcmann; Latifa Bakiri; Helia B Schonthaler; Maria Sibilia; Erwin F Wagner
Journal:  Genes Dev       Date:  2009-11-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.